← Back to Search

Macrolide Antibiotic

Arm 1: Hydroxychloroquine Sulfate + Azithromycin for COVID-19

Phase 2
Waitlist Available
Led By Sabiha Hussain, MD
Research Sponsored by Rutgers, The State University of New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

This trial is testing whether hydroxychloroquine or a combination of hydroxychloroquine and azithromycin is more effective than a delayed hydroxychloroquine regimen in eliminating the SARS-CoV-2 virus.

Eligible Conditions
  • COVID-19
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Changes in Patients Viral Load
Secondary outcome measures
Assessment of agent toxicity
Blood Sample collections
Cytokines in blood
+8 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm 2: Hydroxychloroquine Sulfate aloneExperimental Treatment1 Intervention
• Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days
Group II: Arm 1: Hydroxychloroquine Sulfate + AzithromycinExperimental Treatment2 Interventions
Hydroxychloroquine sulfate 200 mg taken by mouth three (3) times a day for 10 days Azithromycin 500 mg taken by mouth on Day 1, followed by Azithromycin 250 mg taken by mouth once (1) time a day for four (4) days.
Group III: Arm 3: PlaceboActive Control1 Intervention
Placebo pills Days 1-6. If you still have COVID-19 symptoms you will receive Hydroxychloroquine sulfate 200 mg by mouth three (3) times a day for 10 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Hydroxychloroquine
FDA approved

Find a Location

Who is running the clinical trial?

Rutgers, The State University of New JerseyLead Sponsor
429 Previous Clinical Trials
64,193 Total Patients Enrolled
10 Trials studying COVID-19
1,132 Patients Enrolled for COVID-19
Sabiha Hussain, MDPrincipal InvestigatorRutgers, The State University of New Jersey
Steven K. Libutti, MD, FACSStudy ChairRutgers Cancer Institute of New Jersey

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
Sabiha Hussain, MD,MPH 2020. "Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04336332.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top